🔎 Trials Near Me

Home › Amyloidosis › Minnesota

Amyloidosis clinical trials in Minnesota

10 studies for Amyloidosis are looking for participants at sites in Minnesota.

Cities in Minnesota

Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis

  • Research Site, Rochester
RecruitingObservational study
Ages 18 to 130 · All sexes · Updated Sep 23, 2026 · NCT06465810

TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

  • Clinical Trial Site, Rochester
RecruitingPhase 3
Ages 18 to 85 · All sexes · Updated Sep 16, 2026 · NCT07052903

TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy

  • Clinical Trial Site, Rochester
RecruitingPhase 3
Ages 18 to 85 · All sexes · Updated Sep 15, 2026 · NCT07223203

Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

  • Mayo Clinic - Rochester, Rochester
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Aug 4, 2026 · NCT06563895

A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.

  • Research Site, Rochester
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 2, 2026 · NCT07081646

MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

  • Mayo Clinic, Rochester
RecruitingPhase 3
Ages 18 to 90 · All sexes · Updated Mar 27, 2026 · NCT06128629

A Study Of Myocardial Stiffness In Amyloidosis With Magnetic Resonance Elastography

  • Mayo Clinic, Rochester
RecruitingObservational study
Ages 20 and older · All sexes · Updated Dec 26, 2025 · NCT07216469

A Study Of MCG In Cardiac Amyloidosis

  • Mayo Clinic in Rochester, Rochester
RecruitingObservational study
Ages 18 and older · All sexes · Updated Dec 22, 2025 · NCT07218705

From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.